Big pharma's future: panel discussion
This article was originally published in Scrip
Big pharma companies are expected to turn a corner in 2016, when the decline in prescription drug revenues should stem, with a return to annual growth then forecast. This is the finding of a new report, The Outlook for Big Pharma, published by Datamonitor Healthcare, in which revenues from a group of 16 top big pharma companies are forecast to grow from $439bn in 2014 to $499bn in 2024.
You may also be interested in...
Dr Reddy’s Laboratories has become the third Revlimid ANDA sponsor to settle patent litigation action with Bristol Myers Squibb’s Celgene. However, the Indian company will join Alvogen in not being able to launch before first settler Natco, which has partnered with Teva’s Watson.
Strides is expanding its presence in synthetic injectables via a new company, SteriScience, while keeping its biologics injectables business under Stelis. A head start with existing IP assets and those from a new joint venture with Brooks Labs will enable the fledgling firm to file its first ANDA in fiscal 2021, with break-even foreseen in two years.
The US FDA has been skeptical about remote testing, but independent consultant (and former Abbott human factors director) Ed Israelski predicts the pandemic may bring a change.